• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Singer Nicholas Jason converted options into 421,759 shares and disposed of 421,759 shares

    5/20/22 4:35:08 PM ET
    $OTRA
    Get the next $OTRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Singer Nicholas Jason

    (Last) (First) (Middle)
    1395 BRICKELL AVENUE
    SUITE 800

    (Street)
    MIAMI FL 33131

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OTR Acquisition Corp. [ OTRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 05/20/2022 C 421,759 A (1)(4) 421,759 I PC SPAC Holdings LLC
    Class A Common Stock 05/20/2022 J 421,759 D (7) 0 I PC SPAC Holdings LLC
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Common Stock (1) 05/20/2022 J(2) 1,305,918 (1) (1) Class A Common Stock 1,305,918 $0.00 421,759 I See Footnote(3)
    Class B Common Stock (1)(4) 05/20/2022 C 421,759 (1)(4) (1)(4) Class A Common Stock 421,759 $0.00 0 I PC SPAC Holdings LLC
    Warrants (5) 05/20/2022 J 762,634 (6) (6) Class A Common Stock 762,634 $0.00 0 I PC SPAC Holdings LLC
    Explanation of Responses:
    1. As described in the OTR Acquisition Corp.'s registration statement on Form S-1 (File No. 333-248093) under the heading "Description of Securities," the Class B common stock, par value U.S. $0.0001 per share, of the issuer (the "Founder Shares") automatically convert into Class A common stock of the issuer ("Class A Common Stock") at the time of the issuer's initial business combination or earlier at the option of the holders thereof, on a one-for-one basis, subject to certain adjustments described therein, and have no expiration date.
    2. On May 19, 2022, OTR Acquisition Sponsor LLC (the "Sponsor") entered into a certain second amended and restated limited liability operating agreement (the "Amended LLC Agreement"). Prior to the Amended LLC Agreement, PC SPAC Holdings LLC, an entity controlled by the reporting person, was the sole managing member of the Sponsor. The Amended LLC Agreement provides that the Sponsor be managed by a board of managers consisting of three persons, including the reporting person. For the purposes of Rule 16a-(1), the reporting person is no longer a beneficial owner of the 1,305,918 shares of Class B common stock, par value U.S. $0.0001 per share, of OTR Acquisition Corp. held directly by the Sponsor, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
    3. The securities are held indirectly by Nicholas J. Singer, who has sole voting and dispositive control of PC SPAC Holdings LLC.
    4. On May 20, 2022, the issuer consummated its initial business combination (the "Business Combination") with Comera Life Sciences Holdings, Inc.. ("Holdco"), a Delaware corporation. In connection with the Business Combination, each Founder Share converted into Class A Common Stock.
    5. In connection with the Business Combination closing, the reporting person exchanged each of its warrants to purchase the issuer's Class A Common Stock on a one for one basis for an aggregate of 762,634 warrants to purchase shares of Holdco's common stock, par value U.S. $0.0001 per share ("Holdco Common Stock"), at a purchase price of $11.50 per share.
    6. The warrants were not exercisable until 30 days after the issuer's initial business combination and would have expired five years from the consummation of the issuer's initial business combination.
    7. In connection with the Business Combination closing, the reporting person exchanged each its shares of Class A Common Stock for 421,759 fully paid and non-assessable shares of Holdco Common Stock.
    /s/ Nicholas J. Singer 05/20/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OTRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

    – Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

    5/20/22 8:00:00 AM ET
    $OTRA
    $OTRAU
    Business Services
    Finance

    Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation

    Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

    5/9/22 8:00:00 AM ET
    $OTRA

    Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo

    Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

    4/27/22 8:00:00 AM ET
    $OTRA

    $OTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Gray Glenn Evan converted options into 22,123 shares and disposed of 100,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:37:26 PM ET
    $OTRA

    SEC Form 4: Otr Acquisition Sponsor Llc converted options into 1,305,918 shares and disposed of 1,305,918 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:35:50 PM ET
    $OTRA

    SEC Form 4: Besner Nadav converted options into 5,000 shares and disposed of 5,000 shares

    4 - OTR Acquisition Corp. (0001821318) (Issuer)

    5/20/22 4:36:27 PM ET
    $OTRA

    $OTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    1/24/23 9:57:09 AM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/20/22 4:37:55 PM ET
    $OTRA

    SEC Form SC 13G/A filed by OTR Acquisition Corp. (Amendment)

    SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

    5/10/22 4:19:44 PM ET
    $OTRA

    $OTRA
    SEC Filings

    View All

    SEC Form 15-12B filed by OTR Acquisition Corp.

    15-12B - OTR Acquisition Corp. (0001821318) (Filer)

    5/31/22 8:00:30 AM ET
    $OTRA

    OTR Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OTR Acquisition Corp. (0001821318) (Filer)

    5/24/22 4:31:11 PM ET
    $OTRA

    SEC Form 25-NSE filed by OTR Acquisition Corp.

    25-NSE - OTR Acquisition Corp. (0001821318) (Subject)

    5/19/22 4:06:33 PM ET
    $OTRA